S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Why This Bear Market Is Not Even Close to Being Done…
Tailor an Options Trading Strategy to Fit Your Needs (Ad)pixel
Denmark says Nord Stream 1 natural gas pipeline has also stopped leaking
Denmark says Nord Stream 1 pipelines stop leaking
Tailor an Options Trading Strategy to Fit Your Needs (Ad)pixel
Brazil holds historic election with Lula against Bolsonaro
US shift away from coal hits tribal community in New Mexico
An All-In-One Guide for Trading Metals (Ad)pixel
Allies aim for risky Russian oil price cap as winter nears
Tesla sales bounce back in Q3 but fall short of estimates
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Why This Bear Market Is Not Even Close to Being Done…
Tailor an Options Trading Strategy to Fit Your Needs (Ad)pixel
Denmark says Nord Stream 1 natural gas pipeline has also stopped leaking
Denmark says Nord Stream 1 pipelines stop leaking
Tailor an Options Trading Strategy to Fit Your Needs (Ad)pixel
Brazil holds historic election with Lula against Bolsonaro
US shift away from coal hits tribal community in New Mexico
An All-In-One Guide for Trading Metals (Ad)pixel
Allies aim for risky Russian oil price cap as winter nears
Tesla sales bounce back in Q3 but fall short of estimates
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Why This Bear Market Is Not Even Close to Being Done…
Tailor an Options Trading Strategy to Fit Your Needs (Ad)pixel
Denmark says Nord Stream 1 natural gas pipeline has also stopped leaking
Denmark says Nord Stream 1 pipelines stop leaking
Tailor an Options Trading Strategy to Fit Your Needs (Ad)pixel
Brazil holds historic election with Lula against Bolsonaro
US shift away from coal hits tribal community in New Mexico
An All-In-One Guide for Trading Metals (Ad)pixel
Allies aim for risky Russian oil price cap as winter nears
Tesla sales bounce back in Q3 but fall short of estimates
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Why This Bear Market Is Not Even Close to Being Done…
Tailor an Options Trading Strategy to Fit Your Needs (Ad)pixel
Denmark says Nord Stream 1 natural gas pipeline has also stopped leaking
Denmark says Nord Stream 1 pipelines stop leaking
Tailor an Options Trading Strategy to Fit Your Needs (Ad)pixel
Brazil holds historic election with Lula against Bolsonaro
US shift away from coal hits tribal community in New Mexico
An All-In-One Guide for Trading Metals (Ad)pixel
Allies aim for risky Russian oil price cap as winter nears
Tesla sales bounce back in Q3 but fall short of estimates
NASDAQ:ACIU

AC Immune - ACIU Stock Forecast, Price & News

$3.16
-0.13 (-3.95%)
(As of 09/30/2022 12:00 AM ET)
Add
Compare
Today's Range
$2.96
$3.28
50-Day Range
$2.40
$3.64
52-Week Range
$2.06
$8.14
Volume
93,520 shs
Average Volume
75,408 shs
Market Capitalization
$264.02 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$13.00

AC Immune MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
311.4% Upside
$13.00 Price Target
Short Interest
Bearish
1.05% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.03mentions of AC Immune in the last 14 days
Based on 8 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.01) to ($0.33) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.98 out of 5 stars

Medical Sector

754th out of 1,095 stocks

Pharmaceutical Preparations Industry

368th out of 547 stocks

ACIU stock logo

About AC Immune (NASDAQ:ACIU) Stock

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Phase II clinical prevention trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as completed Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that has completed Phase Ib clinical study; and Tau- positron emission tomography (PET) imaging tracer, which is in Phase II clinical study. In addition, the company is researching and developing small molecule Tau aggregation inhibitors for AD and NeuroOrphan indications. Further, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. AC Immune SA has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; Eli Lilly and Company; and WuXi Biologics. The company was incorporated in 2003 and is headquartered in Lausanne, Switzerland.

Receive ACIU Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AC Immune and its competitors with MarketBeat's FREE daily newsletter.

ACIU Stock News Headlines

AC Immune (NASDAQ:ACIU) Coverage Initiated at StockNews.com
See More Headlines
Receive ACIU Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AC Immune and its competitors with MarketBeat's FREE daily newsletter.

ACIU Company Calendar

Last Earnings
7/28/2022
Today
10/02/2022
Next Earnings (Estimated)
11/14/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ACIU
Employees
137
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$13.00
High Stock Price Forecast
$16.00
Low Stock Price Forecast
$10.00
Forecasted Upside/Downside
+311.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-79,860,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$16.46 million
Book Value
$3.49 per share

Miscellaneous

Free Float
N/A
Market Cap
$264.02 million
Optionable
Not Optionable
Beta
0.72

Key Executives

  • Dr. Andrea Pfeifer Ph.D. (Age 65)
    Co-Founder, CEO & Director
    Comp: $1.23M
  • Mr. Piergiorgio Donati (Age 51)
    Chief Technical Operations Officer
  • Dr. Marie Kosco-Vilbois (Age 64)
    Chief Scientific Officer
  • Mr. Jean-Fabien Monin (Age 51)
    Chief Admin. Officer
  • Prof. Johannes Rolf Streffer M.D. (Age 53)
    Chief Medical Officer
  • Mr. Christopher Roberts
    Interim CFO & VP of Fin.
  • Mr. Joshua Drumm Ph.D.
    Head of Investor Relations
  • Mr. Alexandre Caratsch (Age 56)
    Gen. Counsel
  • Judith Moore
    Global Head of Communications
  • Mr. Julian Snow
    VP of U.S. Fin. & Corp. Devel.













ACIU Stock - Frequently Asked Questions

Should I buy or sell AC Immune stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for AC Immune in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ACIU shares.
View ACIU analyst ratings
or view top-rated stocks.

What is AC Immune's stock price forecast for 2022?

2 analysts have issued 1 year price objectives for AC Immune's stock. Their ACIU share price forecasts range from $10.00 to $16.00. On average, they anticipate the company's share price to reach $13.00 in the next year. This suggests a possible upside of 311.4% from the stock's current price.
View analysts price targets for ACIU
or view top-rated stocks among Wall Street analysts.

How have ACIU shares performed in 2022?

AC Immune's stock was trading at $4.95 on January 1st, 2022. Since then, ACIU shares have decreased by 36.2% and is now trading at $3.16.
View the best growth stocks for 2022 here
.

When is AC Immune's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 14th 2022.
View our ACIU earnings forecast
.

How were AC Immune's earnings last quarter?

AC Immune SA (NASDAQ:ACIU) released its earnings results on Thursday, July, 28th. The company reported ($0.24) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.24).

What is Andrea Pfeifer's approval rating as AC Immune's CEO?

3 employees have rated AC Immune Chief Executive Officer Andrea Pfeifer on Glassdoor.com. Andrea Pfeifer has an approval rating of 35% among the company's employees. This puts Andrea Pfeifer in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of AC Immune own?
When did AC Immune IPO?

(ACIU) raised $55 million in an initial public offering on Friday, September 23rd 2016. The company issued 4,600,000 shares at a price of $11.00-$13.00 per share. Credit Suisse, Jefferies and Leerink Partners served as the underwriters for the IPO.

What is AC Immune's stock symbol?

AC Immune trades on the NASDAQ under the ticker symbol "ACIU."

How do I buy shares of AC Immune?

Shares of ACIU stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is AC Immune's stock price today?

One share of ACIU stock can currently be purchased for approximately $3.16.

How much money does AC Immune make?

AC Immune (NASDAQ:ACIU) has a market capitalization of $264.02 million and generates $16.46 million in revenue each year. The company earns $-79,860,000.00 in net income (profit) each year or ($1.01) on an earnings per share basis.

How many employees does AC Immune have?

The company employs 137 workers across the globe.

How can I contact AC Immune?

AC Immune's mailing address is EPFL Innovation Park Building B, Lausanne V8, 1015. The official website for the company is www.acimmune.com. The company can be reached via phone at (121) 693-9121, via email at ir@acimmune.com, or via fax at 41-21-345-9120.

This page (NASDAQ:ACIU) was last updated on 10/2/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.